Vir Biotechnology (VIR) is a clinical-stage immunology company focused on treating and preventing serious infectious diseases. The company has a multi-program and multi-technology platform approach towards the application of immunology towards infectious diseases. Vir recently brought itself public via an IPO that was a major flop. Shares have since declined to what is likely to represent an opportunity.
Vir's IPO was muddied by SoftBank/WeWork
SoftBank owns around 19.8 percent of Vir. SoftBank's Vision Fund has been an investor in Vir for years and was also involved in the company's $416 million funding round